natgillin/translations-raw huggingface dataset:
Age &gt; 75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment.
Dob starija od 75 godina i demencija vaskularnog/miješanog tipa bili su prepoznati kao čimbenici rizika za CVAE povezane s liječenjem olanzapinom.
Age greater than 75 years was a significant predictor of carboxy- and desmethyl- dabrafenib plasma concentrations with a 40% greater exposure in subjects ≥75 years of age, relative to subjects &lt; 75 years old.
Dob iznad 75 godina bila je značajan prediktor koncentracije karboksi- i dezmetil- dabrafeniba u plazmi s 40% jačom izloženosti u ispitanika ≥ 75 godina starosti, u usporedbi s ispitanicima &lt; 75 godina.
Age group 4 (n=45): 1 to &lt; 2 years treated with daptomycin dosed at 10 mg/kg or SOC.
Dobna skupina 4 (n=45): 1 do &lt; 2 godine liječeni daptomicinom u dozi od 10 mg/kg ili SOC.
Age group 65 - &lt; 75years
Dobna skupina od 65 - &lt; 75godina
Age Group ≥2 months to &lt; 3 years
Dobna skupina ≥2 mjeseca do &lt; 3 godine
Age Group ≥3 to &lt; 18 years
Dobna skupina ≥3 do &lt; 18 godina
Age, gender, race or body mass index (≥30 kg/m2, &lt; 30 kg/m2) did not influence the response to amlodipine/valsartan.
Dob, spol, rasa ili indeks tjelesne mase (≥30 kg/m2, &lt; 30 kg/m2) nisu utjecali na odgovor na amlodipin/valsartan.
Age, gender, race or body mass index (≥30 kg/m2, &lt; 30 kg/m2) did not influence the response to Copalia.
Dob, spol, rasa ili indeks tjelesne mase (≥30 kg/m2, &lt; 30 kg/m2) nisu utjecali na odgovor na Copaliu.
Age, gender, race or body mass index (≥30 kg/m2, &lt; 30 kg/m2) did not influence the response to Dafiro.
Dob, spol, rasa ili indeks tjelesne mase (≥30 kg/m2, &lt; 30 kg/m2) nisu utjecali na odgovor na Dafiro.
Age, gender, race or body mass index (≥30 kg/m2, &lt; 30 kg/m2) did not influence the response to Exforge.
Dob, spol, rasa ili indeks tjelesne mase (≥30 kg/m2, &lt; 30 kg/m2) nisu utjecali na odgovor na Exforge.
Age: Based on the population pharmacokinetic analysis of data for 232 patients aged ≥ 65 years and 343 patients aged &lt; 65 years, age has no statistically significant effect on bexarotene pharmacokinetics.
Dob: Na temelju populacijske farmakokinetičke analize podataka prikupljenih u 232 bolesnika u dobi od ≥ 65 godina i 343 bolesnika u dobi od &lt; 65 godina, dob nema statistički značajan učinak na farmakokinetiku beksarotena.
Aged &lt; 8 years
U dobi od &lt; 8 godina
Agranulocytosis (≥ 1/1000 to &lt; 1/100) and neutropenia have been reported; therefore, regular monitoring of patients taking Myclausen is advised (see section 4.4).
Prijavljene su agranulocitoza (≥ 1/1000 do &lt; 1/100) i neutropenija, stoga se preporučuje redovito praćenje bolesnika koji uzimaju Myclausen (vidjeti dio 4.4).
Agranulocytosis (≥1/1000 to &lt; 1/100) and neutropenia have been reported; therefore regular monitoring of patients taking CellCept is advised (see section 4.4).
Prijavljene su agranulocitoza (≥1/1000 i &lt; 1/100) i neutropenija, stoga se preporučuje redovito praćenje bolesnika koji uzimaju CellCept (vidjeti dio 4.4).
Agranulocytosis (≥1/1000 to &lt; 1/100) and neutropenia have been reported; therefore regular monitoring of patients taking Myfenax is advised (see section 4.4).
Prijavljene su agranulocitoza (manje često) i neutropenija, stoga se preporučuje redovito praćenje bolesnika koji uzimaju Myfenax (vidjeti dio 4.4).
Agranulocytosis (≥1/1000 to &lt; 1/100) and neutropenia have been reported; therefore, regular monitoring of patients taking CellCept is advised (see section 4.4).
Prijavljene su agranulocitoza (≥1/1000 i &lt; 1/100) i neutropenija, stoga se preporučuje redovito praćenje bolesnika koji uzimaju CellCept (vidjeti dio 4.4).
Agranulocytosis has been reported very rarely ( &lt; 1/10,000 patients) during post-marketing surveillance.
Tijekom postmarketinškog praćenja, agranulocitoza je bila prijavljena vrlo rijetko ( &lt; 1/10 000 bolesnika).
Air travel ( &gt; 4 hours) may temporarily increase your risk of a blood clot, particularly if you have some of the other factors listed.
Putovanje avionom (duže od 4 sata) može Vam privremeno povećati rizik od krvnog ugruška, osobito ako imate neke druge od navedenih čimbenika.
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation &gt; 5 times upper limit of normal (ULN) with total bilirubin ≤2 times ULN
Povišenje alanin aminotransferaze (ALT) ili aspartat aminotransferaze (AST) &gt; 5 puta iznad gornje granice normale (GGN) uz ukupni bilirubin ≤2 puta GGN
Alanine aminotransferase increased (SGPT &gt; 5 times baseline)   * °
Povećana alanin aminotransferaza (SGPT &gt; 5 puta više od početne vrijednosti)   * °
Albumin &lt; 0.75 LLN or UPC &gt; 2 (2nd time)
Albumin &lt; 0.75 DGN ili UPC &gt; 2 (2. put)
Albumin &lt; 0.75 LLN or UPC &gt; 2 (1st time)
Albumin &lt; 0.75 DGN ili UPC &gt; 2 (1. put)
Albumin &lt; 0.75 LLN or UPC &gt; 2 (1st time)
Albumin &lt; 0.75 DGN or UPC &gt; 2 (1. put)
Albumin &lt; 1 LLN or UPC &gt; 2
Albumin &lt; 1 DGN ili UPC &gt; 2
Albumin &lt; 1.5 g/dl
Albumin &lt; 1,5 g/dl
Alemtuzumab 12 mg/day led to significantly lower EDSS scores (improved compared to baseline) through 2 years of follow up, compared with IFNB-1a (p &lt; 0.0001).
Alemtuzumab u dozi od 12 mg/dan je tijekom 2 godine kontrolnog praćenja doveo do značajno nižeg EDSS rezultata (poboljšanje u odnosu na početne vrijednosti) u usporedbi s IFNB-1a (p &lt; 0,0001).
Alfred Gera &amp; Sons Ltd.
MEDA PHARMA Hungary Kereskedelmi Kft.
Aliskiren is not recommended in patients with severe renal impairment (glomerular filtration rate (GFR) &lt; 30 ml/min/1.73 m2).
Aliskiren se ne preporučuje bolesnicima s teškim oštećenjem bubrežne funkcije (brzina glomerularne filtracije (GFR) &lt; 30 ml/min/1,73 m2).
ALKP &lt; 2 x ULN) treatment with Vargatef should be interrupted.
≥ 2 x GGN i AP &lt; 2 x GGN) mora se prekinuti liječenje Vargatefom.
All 28 patients (100%) treated after withdrawal of THST and all 32 patients (100%) treated after Thyrogen administration had either no visible uptake of radioiodine in the thyroid bed or, if visible, thyroid bed uptake &lt; 0.1% of the administered activity of radioiodine.
U svih 28 bolesnika (100%) liječenih nakon prekida supresijske terapije tireoidnim hormonom te u svih 32 bolesnika (100%) liječenih nakon primjene lijeka Thyrogen ili nije bilo vidljivog nakupljanja radioaktivnog joda u ležištu štitnjače ili ono, ako je bilo vidljivo, nije premašilo &lt; 0,1% primijenjene aktivnosti radioaktivnog joda.
All 5 patients had maximum ALT or AST levels &gt; 8 x ULN, which returned to baseline levels following interruption of dosing with ivacaftor granules.
Svih 5 bolesnika imalo je maksimalne razine ALT ili AST &gt; 8 puta GGN, koje su se vratile na početne razine nakon prekida primjene granula ivakaftora.
All 61 patients had HBsAg loss post-transplantation, and 2 of these later became HBsAg positive despite maintaining undetectable HBV DNA ( &lt; 6 IU/ml).
U svih 61 bolesnika nastupio je nestanak HBsAg nakon transplantacije, dok su 2 od tih bolesnika kasnije postali HBsAg pozitivni usprkos tome što su i dalje imali nemjerljiv HBV DNK ( &lt; 6 IU/ml).
All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Sve nuspojave navedene su prema klasifikaciji organskih sustava i učestalosti; vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
All adverse reactions are listed by System Organ Class and frequency: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); and rare (≥1/10,000 to &lt; 1/1,000).
Sve su nuspojave razvrstane prema klasifikaciji organskih sustava i učestalosti: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100) i rijetko (≥1/10 000 i &lt; 1/1000).
All adverse reactions are listed by system organ class and frequency; very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100) and rare ( 1/10,000 to &lt; 1/1,000).
Sve su nuspojave popisane prema organskim sustavima i učestalosti; vrlo često ( 1/10), često ( 1/100 i &lt; 1/10), manje često ( 1/1000 i &lt; 1/100) te rijetko ( 1/10 000 i &lt; 1/1000).
All bleeding events ≥ grade 2 occurred at platelet counts &lt; 50 x 109/l.
Svi događaji krvarenja (≥ stupanj 2) dogodili su se kad je broj trombocita bio &lt; 50 x 109/l.
All efficacy comparisons vs Placebo + MTX. ***p≤0.0001; **p &lt; 0.001; *p &lt; 0.05;
Sve usporedbe djelotvornosti naspram placeba + MTX-a. ***p≤0,0001; **p &lt; 0,001; *p &lt; 0,05;
All events occurring in the following age groups: 6-23 months, 2-8 years, 8-17 years, 18-60 years, &gt; 60 years
Svi događaji u sljedećim dobnim skupinama: 6-23 mjeseca, 2-8 godina, 8-17 godina, 18-60 godina, &gt; 60 godina
All findings in the non-clinical safety programme have been related to expected exaggerated pharmacology (general thrombosis, ischaemic necrosis and ultimately mortality) of rFXIII and non-proteolytically activated recombinant FXIII at dose levels in excess ( &gt; 48 fold) of the maximum recommended clinical dose of 35 IU/kg.
Sva otkrića u nekliničkom programu sigurnosti odnosila su se na očekivanu pretjeranu farmakološku aktivnost (tromboze, ishemijska nekroza i u krajnjem slučaju smrtnost) rFXIII i neproteolitičkog aktiviranog rekombinantnog FXIII pri razinama doza koje prelaze ( &gt; 48 puta) maksimalnu preporučenu kliničku dozu od 35 IU/kg.
All p-values &lt; 0.001 for all comparisons between Xiapex and placebo, except for PIP joints in Study CORD II which was not eligible for statistical testing due to a hierarchical testing procedure.
Sve p-vrijednosti bile su &lt; 0,001 za sve usporedbe između Xiapexa i placeba, osim PIP zglobova u ispitivanju CORD II koji nisu bili pogodni za statističko testiranje zbog hijerarhijskog postupka testiranja.
All p-values are 2-sided. b Snapshot 26SEP11, Minimum follow-up time: 24 months c Snapshot 31AUG10, Minimum follow-up time: 12 months d MMR (3 log sensitivity) is defined as [(BCR Copies/Abl copies)IS] &lt; /= 0.001 and ABL copies &gt; /= 3,000 and CMR (4.5 log sensitivity) is defined as [(BCR Copies/Abl copies)IS] &lt; /= 0.000032 and ABL
Sve p-vrijednosti su dvostrane. b Prikaz stanja na 26. rujna 2011., minimalno vrijeme praćenja: 24 mjeseca c Prikaz stanja na 31. kolovoza 2010., minimalno vrijeme praćenja: 12 mjeseci d MMR (osjetljivost zapisa 3) definira se kao [(kopije Bcr-a/kopije Abl-a)IS] &lt; /= 0,001 i kopije Abl-a &gt; /= 3000 i CMR (osjetljivost zapisa 4,5) definira se kao [(kopije Bcr-a/kopije Abl-a)IS] &lt; /= 0,000032 i kopije Abl-a
All patients had baseline testosterone levels &lt; 50 ng/mL.
Početna razina testosterona u svih bolesnika bila je &lt; 50 ng / ml.
All patients had ≥ 20% reduction in spleen volume after 18 months, and the vast majority (16/18) of patients achieved &gt; 30% reduction in spleen volume.
Svi bolesnici imali su ≥ 20% smanjenje volumena slezene nakon 18 mjeseci, a velika većina (16/18) bolesnika postigla je &gt; 30% smanjenje volumena slezene.
All patients met Rome II criteria for IBS-C and were required to report a mean abdominal pain score of ≥ 3 on a 0-to-10-point numeric rating scale (criteria that correspond to a moderate to severe IBS population), &lt; 3 complete spontaneous bowel movements and ≤ 5 SBMs per week during a 2-week baseline period.
Svi bolesnici su ispunjavali kriterije Rome II za IBS-C te su prijavili srednju vrijednost intenziteta boli u abdomenu od ≥ 3 na numeričkoj ljestvici 0-10 (kriteriji koji odgovaraju umjerenom do jakom intenzitetu boli kod populacije s IBS-om), &lt; 3 potpuna spontana pražnjenja crijeva i ≤ 5 spontanih pražnjenja crijeva tjedno za vrijeme početnog razdoblja u trajanju od 2 tjedna.
All patients met Rome III criteria for IBS and were required to meet the following criteria: an average of worst abdominal pain (WAP) scores in the past 24 hours of &gt; 3.0 on a 0 to 10 scale over the week prior to randomization. an average daily stool consistency score (BSS) of ≥5.5 and at least 5 days with a BSS score ≥5
Svi su bolesnici zadovoljili Rimske kriterije III za IBS, a morali su zadovoljiti i sljedeće kriterije: prosječni bodovi najgore boli u abdomenu (eng. worst abdominal pain, WAP) u posljednja 24 sata od &gt; 3,0 na ljestvici od 0 do 10 tijekom tjedna prije randomizacije. prosječni dnevni bodovi konzistencije stolice (BSS) od ≥5,5 i najmanje 5 dana s BSS bodovima
All patients were required to be ambulatory, defined as the ability to walk for ≥75 meters without the need for assistive devices during a screening 6-minute Walk Test (6MWT).
Svi bolesnici su morali biti pokretni, što je definirano sposobnošću hodanja &gt; 75 metara bez potrebe pomagala tijekom probirnog 6-minutnog testa hoda.
All PRs achieved; p &lt; 0.0001 for ORR.
Svi postignuti djelomični odgovori; p &lt; 0,0001 za ukupnu stopu odgovora.
All six fatal hypersensitivity cases were reported in the US and involved elderly patients ( &gt; 65 years of age) with co-morbidities.
Svih šest slučajeva preosjetljivosti sa smrtnim ishodom prijavljeno je u SAD-u, a radilo se o starijim bolesnicima (u dobi od &gt; 65 godina) s komorbiditetima.
All subjects had severe (factor IX level &lt; 1%) or moderately severe (factor IX level ≤2%) haemophilia B. Fifty-nine PTPs received RIXUBIS for prophylaxis.
Svi su ispitanici imali tešku (razina faktora IX &lt; 1%) ili umjereno tešku (razina faktora IX ≤2%) hemofiliju B. Pedeset i devet prethodno liječenih bolesnika primilo je lijek RIXUBIS za profilaksu.
All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160 mg at Week 0 and 80 mg at Week 2 for subjects ≥ 40 kg, and 80 mg and 40 mg, respectively, for subjects &lt; 40 kg.
Svi ispitanici su primali otvorenu indukcijsku terapiju u dozi određenoj prema njihovoj početnoj tjelesnoj težini: 160 mg u nultom tjednu i 80 mg u drugom tjednu za ispitanike tjelesne težine ≥ 40 kg, odnosno 80 mg i 40 mg za ispitanike tjelesne težine &lt; 40 kg.
All tested doses of INVEGA separated from placebo on day 4 (p &lt; 0.05).
Sve su se ispitivane doze INVEGE razlikovale od placeba na 4. dan (p &lt; 0,05).
All three strengths of Instanyl showed statistically significant (p &lt; 0.001) higher pain intensity difference at 10 minutes (PID10) compared with placebo.
Sve tri jačine Instanyla pokazale su statistički značajno (p &lt; 0,001) višu razliku intenziteta boli nakon 10 minuta (RIB10) u usporedbi s placebom.
All three strengths of Instanyl showed statistically significant (p0.001) higher pain intensity difference at 10 minutes (PID10) compared with placebo.
Sve tri jačine Instanyla pokazale su statistički značajno (p &lt; 0,001) višu razliku intenziteta boli nakon 10 minuta (RIB10) u usporedbi s placebom.
All upper limits of the 90% CI for the LS mean change from Baseline in QTcF at all Cycle 2 Day 1 time points were &lt; 20 msec.
Sve gornje granice 90%-tnog CI za srednju vrijednost promjene dobivenu metodom najmanjih kvadrata u odnosu na početne vrijednosti QTcF-intervala u svim vremenskim točkama 1. dana 2. ciklusa bile su &lt; 20 msek.
All-cause mortality (adjudicated deaths) per renal subgroups (edoxaban vs. warfarin): CrCL 30 to ≤ 50 mL/min [HR (95% CI): 0.81 (0.68, 0.97)]; CrCL &gt; 50 to &lt; 80 mL/min [HR (95% CI): 0.87 (0.75,
Mortalitet bilo kojeg uzroka (pripisane smrti) u podskupinama prema bubrežnoj funkciji (edoksaban naspram varfarin): CrCL od 30 do ≤ 50 ml/min [HR (95% CI): 0,81 (0,68, 0,97)]; CrCL od &gt; 50 do
Almost all fevers after primary and booster doses were mild or moderate ( &lt; 39.5°C) and transient (duration of ≤2 days).
Gotovo svi slučajevi vrućice nakon primarne i doze docjepljivanja bili su blagi ili umjereni ( &lt; 39,5°C) te prolazni (trajali su ≤2 dana).
Almost all fevers were mild or moderate ( &lt; 39.5°C) and transient (duration of ≤2 days). (See section 4.8).
Gotovo svi slučajevi vrućice bili su blagi ili umjereni ( &lt; 39,5°C) te prolazni (trajali su ≤2 dana). (vidjeti dio 4.8).
Almost half (45.8 %) of the RE-LY patients had a CrCL &gt; 50- &lt; 80 mL/min.
Gotovo polovina (45,8 %) ispitanika imala je CrCL &gt; 50- &lt; 80 mL/min.
Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.2 and 5.2).
Alogliptin nije ispitan u bolesnika s teškim oštećenjem jetre (Child-Pugh indeks &gt; 9) te se stoga u takvih bolesnika njegova primjena ne preporučuje (vidjeti dijelove 4.2 i 5.2).
Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.4 and 5.2).
Alogliptin nije ispitan u bolesnika s teškim oštećenjem jetre (Child-Pugh indeks &gt; 9) te se stoga u takvih bolesnika njegova primjena ne preporučuje (vidjeti dijelove 4.4 i 5.2).
Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9).
Alogliptin nije ispitan u bolesnika sa teškim oštećenjem jetre (Child-Pugh indeks &gt; 9).
Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9, see section 4.2).
Alogliptin nije ispitan u bolesnika sa teškim oštećenjem jetre (Child-Pugh indeks &gt; 9, vidjeti dio 4.2).
Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.2, 4.3 and 5.2).
Alogliptin nije ispitan u bolesnika s teškim oštećenjem jetre (Child-Pugh indeks &gt; 9) te se u tih bolesnika njegova primjena ne preporučuje (vidjeti dijelove 4.2, 4.3 i 5.2).
Alogliptin is a potent and highly selective inhibitor of DPP-4, &gt; 10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9.
Alogliptin je potentan i visoko selektivan inhibitor DPP-4, &gt; 10 000 puta većom selektivnošću za DPP-4 nego za druge srodne enzime, uključujući DPP-8 i DPP-9.
Alogliptin is a potent and highly selective inhibitor of DPP-4, &gt; 10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9.
Alogliptin je potentan i visoko selektivan inhibitor DPP-4, s &gt; 10 000 puta većom selektivnošću za DPP-4 nego za druge srodne enzime, uključujući DPP-8 i DPP-9.
Alogliptin is a potent and highly selective inhibitor of DPP-4, &gt; 10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9.
Alogliptin je potentan i visoko selektivan inhibitor DPP-4, sa &gt; 10 000 puta većom selektivnošću za DPP-4 nego za druge srodne enzime, uključujući DPP-8 i DPP-9.
Alopecia was observed in &gt; 80% of the patients treated with Abraxane.
Alopecija je opažena u &gt; 80% bolesnika liječenih lijekom Abraxane.
ALPROLIX 3000 IU powder and solvent for solution for injection eftrenonacog alfa recombinant coagulation factor IX, Fc fusion protein
ALPROLIX 3000 IU prašak i otapalo za otopinu za injekciju eftrenonacog alfa fuzijski protein rekombinantnog faktora zgrušavanja krvi IX i Fc fragmenta rekombinantni faktor zgrušavanja krvi IX &lt; (side of outer carton, only) &gt;
Also, lamivudine-refractory patients who achieved HBV DNA &lt; 104 log10 copies/ml by PCR at Week 24 had a lower rate of resistance than those who did not (5-year cumulative probability 17.6% [n= 50] versus 60.5% [n= 135], respectively).
Također, bolesnici s bolešću refrakternom na lamivudin u kojih se postigla vrijednost HBV DNK &lt; 104 log10 kopija/ml mjerena PCR-om u 24. tjednu imali su nižu stopu rezistencije od onih koji nisu postigli tu vrijednost (5-godišnja kumulativna vjerojatnost od 17,6% [n= 50] naspram 60,5% [n= 135]).
Also, lamivudine-refractory patients who achieved HBV DNA &lt; 104 log10 copies/ml by PCR at Week 24 had a lower rate of resistance than those who did not (5-year cumulative probability 17.6% [n=50] versus 60.5% [n=135], respectively).
Također, bolesnici s bolešću refrakternom na lamivudin u kojih se postigla vrijednost HBV DNK &lt; 104 log10 kopija/ml mjerena PCR-om u 24. tjednu imali su nižu stopu rezistencije od onih koji nisu postigli tu vrijednost (5-godišnja kumulativna vjerojatnost od 17,6% [n= 50] naspram 60,5% [n= 135]).
ALT &gt; 3 ULN and TBILI &gt; 2 ULN
ALT &gt; 3 GGN i TBILI &gt; 2 GGN
ALT elevation &gt; 2x baseline and
ALT povišenje &gt; 2x početne vrijednosti i
ALT elevation &gt; 2x baseline and &gt; 10x ULN
ALT povišenje &gt; 2x početne vrijednosti i &gt; 10x GGN
ALT increased ( &lt; 2%)
G3/4 povećanje ALT ( &lt; 2%)
ALT normalisation assessed only in patients with ALT &gt; ULN at baseline.
Normalizacija ALT-a ispitivana je samo u bolesnika s početnim ALT &gt; GGN.
ALT or AST &lt; 3 X upper normal limit
ALT ili AST &lt; trostruka gornja normalna granica
ALT or AST &gt; 3-times ULN with persistent symptoms of hepatic injury noted above.
ALT ili AST &gt; 3 puta GGN s trajnim simptomima oštećenja jetre koji su gore navedeni.
ALT or AST &gt; 5-times ULN for more than 2 weeks
ALT ili AST &gt; 5 puta GGN tijekom više od 2 tjedna
ALT or AST &gt; 8-times ULN
ALT ili AST &gt; 8 puta GGN
ALT ≥ 2 x baseline value and absolute ALT &gt; 500 IU/l
ALT ≥ 2 x početne vrijednosti i apsolutni ALT &gt; 500 IU/l
ALT ≥2 x baseline value; and bilirubin &gt; 2 x ULN and ≥2 x baseline value
ALT ≥2 x početne vrijednosti; i bilirubin &gt; 2 x GGN i ≥2 x početne vrijednosti
ALT  2 x baseline value; and bilirubin &gt; 2 x ULN and  2 x baseline value
ALT ≥2 x početne vrijednosti; i bilirubin &gt; 2 x GGN i ≥2 x početne vrijednosti
ALT 2 x baseline value; and bilirubin &gt; 2 x ULN and 2 x baseline value
ALT ≥2 x početne vrijednosti; i bilirubin &gt; 2 x GGN i ≥2 x početne vrijednosti
Alternatively, 90 mg may be used in patients with a body weight &gt; 100 kg.
Alternativno, doza od 90 mg može biti primijenjena kod bolesnika čija je tjelesna težina &gt; 100 kg.
Although a similar antiviral effect was observed between the abacavir and indinavir containing regimens in terms of proportion of patients with undetectable viral load ( 400 copies/ml; intention to treat analysis (ITT), 47 % versus 49 %; as treated analysis (AT), 86 % versus 94 % for abacavir and indinavir combinations respectively), results favoured the indinavir combination, particularly in the subset of patients with high viral load ( &gt; 100,000 copies/ml at baseline; ITT, 46 % versus 55 %; AT, 84 % versus 93 % for abacavir and indinavir respectively).
Iako je prema udjelu bolesnika s virusnim opterećenjem kojeg se ne može otkriti zamijećen sličan antivirusni učinak režima koji sadrže abakavir i indinavir ( 400 kopija/ml; analiza namjere liječenja (ITT), 47% prema 49%; analiza prema terapiji (AT), 86% prema 94% za kombinacije koje prema redoslijedu navođenja sadrže abakavir i indinavir), rezultati su išli u prilog kombinacija koje sadrže indinavir, osobito u podskupini bolesnika s visokim virusnim opterećenjem ( &gt; 100 000 kopija/ml na početku terapije; ITT, 46% prema 55%; AT, 84% prema 93% za abakavir i indinavir prema redoslijedu navođenja).